Ted Love (Haverford College)
With all the buzz in gene therapy, Sanofi offloads two small molecule sickle cell programs from $11.6B buyout to Global Blood Therapeutics
Standing by a small molecule approach in sickle cell disease even as gene therapy and gene editing players tout landmark breakthroughs, Global Blood Therapeutics has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.